Ver­tex Phar­ma­ceu­ti­cals an­nounced Fri­day af­ter­noon that it won’t move for­ward with its type 1 di­a­betes cell ther­a­py that’s de­liv­ered in a … ...

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Testing across these three characteristics has demonstrated promising results, including >98% concentricity and a twofold improvement in fatigue durability through microstructural refinement. The ...

Vertex Trading Down 1.2 % NASDAQ VERX opened at $35.71 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.04 and a current ratio of 1.04. Vertex, Inc. has a one year low ...